CTVA · 10-Q · 2026Q4 · Full report
Operating Expense Trends
Corteva, Inc. · 2026-11-12 · Importance 54 · Surprise 40 · No source text
R&D expense rose 13% to $397 million in the third quarter of 2026 from $351 million, and increased to $1,126 million for the first nine months from $1,061 million. The R&D increase supported long-term investment plans and reflected higher salaries, contract labor, outside contract research, field, laboratory, and facilities costs, plus unfavorable currency impacts, partly offset by third-party cost recoveries. Nine-month SG&A increased to $2,773 million from $2,632 million, driven by currency, personnel, information technology, legal support, and consulting costs.
Key facts
- Corteva’s third-quarter SG&A was $732 million, or 30% of net sales, in 2026 versus $725 million, or 28%, in 2025; increases in personnel, IT costs and legal support fees were partly offset by lower bad debt, promotion and advertising, consulting and professional fees, and commissions. source
- Corteva’s nine-month SG&A was $2,773 million, or 20% of net sales, in 2026 versus $2,632 million, or 20%, in 2025; increases included unfavorable currency, personnel, IT, legal support, and consulting and professional fees. source
- Corteva’s three-month R&D expense was $397 million, or 16% of net sales, in 2026 versus $351 million, or 13%, in 2025; nine-month R&D was $1,126 million, or 8%, versus $1,061 million, or 8%. source
- Corteva’s nine-month 2026 amortization increase was driven primarily by accelerated amortization for certain trade names retired in the second quarter of 2026. source
- Corteva’s intangible asset amortization was $159 million and $162 million in the third quarters of 2026 and 2025, respectively, and $513 million and $485 million in the first nine months of 2026 and 2025, respectively. source
- Corteva’s R&D expense increase supported its long-term investment plans and was driven mainly by salaries, contract labor, outside contract research, field, lab and facilities costs, and unfavorable currency impacts, partly offset by third-party cost recoveries. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -5.7% | Corteva’s nine-month SG&A was $2,773 million, or 20% of net sales, in 2026 versus $2,632 million, or 20%, in 2025; increases included… |
| margin | negative | realized | -2.0% | Corteva’s third-quarter SG&A was $732 million, or 30% of net sales, in 2026 versus $725 million, or 28%, in 2025; increases in personnel,… |
| operating_income | negative | realized | -0.3% | Corteva’s third-quarter SG&A was $732 million, or 30% of net sales, in 2026 versus $725 million, or 28%, in 2025; increases in personnel,… |